Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05387044
Other study ID # 2022-OligoSBRT-IIT
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 1, 2022
Est. completion date April 30, 2024

Study information

Verified date May 2022
Source Zhejiang Cancer Hospital
Contact Xiaojing Lai
Phone 13819480002
Email laixj@zjcc.org.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The treatment modality with immunotherapy has been the first-line standard treatment for advanced NSCLC. But more than 2/3 patients still develop acquired drug resistance within 5 years of immunotherapy, and more than 1/2 patients are oligoprogressive. Stereotactic body radiation therapy (SBRT) plays a growing role in the management of oligometastatic disease. This study aims to evaluate the efficacy and safety of SBRT for oligoprogressive NSCLC after first line treatment with immune checkpoint inhibitors.


Recruitment information / eligibility

Status Recruiting
Enrollment 28
Est. completion date April 30, 2024
Est. primary completion date April 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age at least 18 years; - ECOG PS 0-1; - Patients with pathologically confirmed stage IV NSCLC by tumor biopsy and/or fine-needle aspiration (AJCC the 8th Edition); - Stable Disease for at least 6 months after first line immunotherapy; - Oligoprogressive disease in 5 or fewer lesions and 3 or fewer organs; - All oligopreogressive lesion = 5cm, and intracranial lesion =3cm or 30cc; - Progressive disease would be amenable to SBRT and without indications for palliative radiotherapy in the opinion of the investigator; - Patients with a history of radiotherapy are eligible if radiotherapy administered more than 4 weeks before study entry; - Adequate organ function prior to enrollment: Adequate bone marrow function: white blood cell (WBC) count = 3.0 * 10 ^ 9/L or neutrophil count = 1.5 * 10 ^ 9/L, platelet count = 100 * 10 ^ 9/L and hemoglobin =90g/L,; Adequate hepatic function: total bilirubin, urea nitrogen and serum creatinine= 1.5 x upper limit of normal (ULN). Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) =2.0 ULN; - Life expectancy of more than 3 months; - Ability to understand and willingness to provide the informed consent and signed informed consent for the use of fresh tumor biopsies before and during the treatment; - Women of childbearing age and men must agree to use effective contraception during the trial. Exclusion Criteria: - History of another malignancy or concurrent malignancy (except for cured non-melanoma skin cancer, low-risk prostate cancer, T1/T2 glottic cancer, stage 0 or I breast cancer, non-invasive bladder cancer, cervical cancer in situ); - Positive for driver genes including EGFR, ALK, and ROS-1; - Mixed small cell with non-small cell lung cancer histology; - Malignant pleural or ascites; - Patients with brain metastasis require intracranial decompression; - Symptoms of spinal cord compression; - Severe autoimmune disease: inflammatory bowel disease (including Crohn's disease and ulcerative colitis), rheumatoid arthritis, scleroderma, systemic lupus erythematosus, Wegener's granulomatosis and related vasculitides; - Symptomatic interstitial lung disease or clinically active infectious/non-infectious pneumonitis. - History of another malignancy or concurrent malignancy; - Active infection, congestive heart failure, or any evidence of myocardial infarction, unstable angina pectoris or cardiac arrhythmia within 6 months prior to enrollment; - The patient is pregnant (confirmed by serum b-HCG if applicable) or is breastfeeding; - Mental disorders, drug abuse, and social condition that may negatively impact compliance in the investigator's opinion.

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
SBRT
Patients with oligoprogressive NSCLC after first line treatment with immune checkpoint inhibitors will be treated with SBRT for all progressing lesions.

Locations

Country Name City State
China Zhejiang Cancer Hospital Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Zhejiang Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progress free survival PFS was defined from the date of enrollment to the date of disease progression two years
Secondary Overall survival OS was defined from the date of enrollment until death by any cause or last follow-up. two years
Secondary Grade 3 or higher toxicity Treatment-related grade 3 or higher adverse events according to CTCAE 5.0. two years
Secondary Time to new metastasis Time to new metastasis was defined from the date of enrollment to the date of new lesion progression. 2 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05543330 - A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC Phase 1/Phase 2
Recruiting NCT04106180 - SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC Phase 2
Recruiting NCT05215548 - Primary Tumor Resection With EGFR TKI for Stage IV NSCLC Phase 2
Recruiting NCT04042558 - A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies Phase 2
Completed NCT04507217 - Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC Phase 2
Recruiting NCT04467801 - Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy Phase 2
Active, not recruiting NCT04027647 - Phase 2 Study of Dacomitinib in NSCLC Phase 2
Recruiting NCT04768491 - Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
Not yet recruiting NCT04492969 - Prospective Observation of Failure Patterns in NSCLC Treated With ICIs
Recruiting NCT04116918 - Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
Terminated NCT03411473 - Study of AGEN1884 With Pembrolizumab in 1L NSCLC Phase 2
Recruiting NCT03564197 - 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC N/A
Not yet recruiting NCT06219317 - Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC Phase 2
Not yet recruiting NCT04604470 - Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2
Recruiting NCT05132218 - Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
Not yet recruiting NCT04136535 - Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC Phase 2
Completed NCT03184571 - Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC Phase 2
Completed NCT06339554 - Alectinib-induced Endocrine Toxicity
Active, not recruiting NCT04549428 - Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC Phase 2
Recruiting NCT03647956 - Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors Phase 2